

One molecule with several therapeutic modalities against cancer (BioRap)

One of the obstacles in clinical oncology is that tumors sometimes acquire resistance to therapy and spread.

Throughout the years, various therapeutic agents have been developed aiming to directly target tumor cells or inhibit tumor-supporting cells in its microenvironment.

The development of immunomodulatory agents and antiangiogenic drugs has made a significant impact on the oncology field in recent years. Yet, it is currently clear that a combinatorial treatment modality against cancer is required in order to enhance therapy outcome and delay resistance and metastasis.

Prof. Yuval Shaked and Prof. Ami Aronheim have worked together to develop a drug which acts against tumor cells and hosts cells at the tumor microenvironment. They have generated a stable recombinant protein which modulate the immune system against tumor cells, inhibits tumor cell proliferation and metastasis and block angiogenesis. This molecule has shown significant anti-tumor and anti-metastatic activities with no toxicity in several aggressive tumor models in mice.

Disease	Type of Molecule	Commercialization
Cancer	recombinant protein	Status Available to licensing

Contact for more information:

Orit Shaked , CEO of BioRap, +972 4 8295402

1 Efron Street
P.O. Box 9697
Haifa 31096, Israel
Tel: 972-4-829-5402
Fax: 972-4-855-2296